Geen internetverbinding — de opgeslagen versie van de pagina wordt getoond.

Neurocrine Biosci…

USUSD
← Naar de screener

Neurocrine Biosciences Inc (MI:1NBIX) — Biotechnology: Biological Products (No Diagnostic Substances). Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 3. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.

Over het bedrijf

Website
neurocrine.com
Sector
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hoofdkantoor
San Diego, United States
CEO
Kyle W. Gano
Werknemers
2 500
Opgericht
1992
Uitstaande aandelen
101.65 mln. per 2026-07-22
Free float
100.37 mln.
Marktkapitalisatie
14.42 mld. USD
Insiders
1.06%
Institutionele beleggers
102.84%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
Rechtsvorm
XTIQ
ISIN
US64125C1099
LEI
549300FECER0XBN49756
FCF
870 mln. USD
Schuld
0
Winst en FCF — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Beurzen en tickers

BeursTickerValutaPrijsType
US USA StocksNBIX primairUSD141.25 -1.55%gewone aandelen
LSE London Stock Exchange0K6R IOBUSD138.12 +0.00%gewone aandelen
MI Borsa Italiana (Milan)1NBIX secundairEUR129.8 -0.15%gewone aandelen

Koers over 3 maanden

stijgingsdag dalingsdagBeweeg over / tik op een dag — openings-, slot-, hoogste en laagste koers

Nieuws deze week

Nog geen nieuws van de website van het bedrijf.

advertentie

Grootste aandeelhouders

HouderBelangAandelenRapportdatum
Blackrock Inc.13.49%13.71 mln.2026-06-30
JPMORGAN CHASE & CO6.29%6.4 mln.2026-06-30
Dodge & Cox Inc.5.49%5.58 mln.2026-06-30
Vanguard Portfolio Manag…4.89%4.97 mln.2026-06-30
Vanguard Capital Managem…4.47%4.55 mln.2026-06-30
State Street Corporation4.31%4.39 mln.2026-06-30
Dodge & Cox Funds-Dodge…3.9%3.96 mln.2026-06-30
AQR Capital Management,…3.76%3.82 mln.2026-06-30
iShares Trust-iShares Co…3.46%3.52 mln.2026-08-31
VANGUARD INDEX FUNDS-Van…3.14%3.19 mln.2026-06-30
Renaissance Technologies…2.3%2.34 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…2.27%2.3 mln.2026-06-30
Geode Capital Management…2.1%2.14 mln.2026-06-30
Two Sigma Investments, L…2.04%2.08 mln.2026-06-30
J.P. Morgan Mutual Fd. I…1.34%1.36 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…1.31%1.33 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…1.13%1.15 mln.2026-06-30
JPMorgan Trust II-JPMorg…1.1%1.12 mln.2026-06-30
iShares Trust-iShares Bi…0.73%739 6702026-08-31
SPDR S&P MIDCAP 400 ETF…0.72%735 3422026-08-31
GORMAN KEVIN CHARLES (Di…≈0.51%517 7972026-09-11
GANO KYLE W (Chief Execu…≈0.15%154 7282026-09-11
LYONS GARY A (Director)≈0.12%122 1412026-05-21
BENEVICH ERIC S. (Office…≈0.07%67 2972026-09-11
LIPPOLDT DARIN M (Office…≈0.06%56 7932026-09-11
RASTETTER WILLIAM H (Dir…≈0.04%43 6782026-05-21
ABERNETHY MATTHEW C (Chi…≈0.04%42 8082026-09-14
POPS RICHARD F (Director…≈0.04%37 7982026-05-21
ROBERTS EIRY WYN (Office…≈0.04%35 6402025-02-14
COOKE JULIE SMITH (Offic…≈0.02%24 0252026-09-11